VCID Biomarker's Coordinating Center

VCID生物标志物协调中心

基本信息

批准号：
9516183
负责人：
Steven M Greenberg
金额：
$ 47.23万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-30 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9516183
关键词：
Age Age-associated memory impairment Alzheimer&apos s Disease Area Biological Biological Markers Biology Blood Vessels Body Fluids Brain Cerebral small vessel disease Clinical Clinical Research Clinical Trials Collaborations Communication Complex Consensus Country Data Data Collection Data Storage and Retrieval Decision Making Dementia Disease Future General Hospitals Goals Impaired cognition Incidence Income Individual Intervention Intervention Trial Lead Leadership Liquid substance Magnetic Resonance Imaging Massachusetts Medical Methods Microvascular Dysfunction National Institute of Neurological Disorders and Stroke Office of Administrative Management Positioning Attribute Prevention Principal Investigator Procedures Public Health Recommendation Regulation Research Research Infrastructure Research Personnel Research Priority Sampling Scanning Site Stroke Structure Technology Testing Training United States National Institutes of Health Validation Variant base biomarker validation cardiovascular health data management design epidemiology study experience innovation international center multimodality outreach response skills validation studies vascular cognitive impairment and dementia

项目摘要

PROJECT SUMMARY/ABSTRACT The vascular contribution to cognitive impairment and dementia (VCID) driven by cerebral small vessel disease (SVD) is now recognized as a major public health threat. In response to the call from NINDS for a multisite consortium dedicated to identifying and validating biomarkers for SVD-related VCID, we propose to form the Massachusetts General Hospital (MGH) VCID Biomarkers Coordinating Center. The aims of the proposed coordinating center will be to provide outstanding scientific leadership and state-of-the-art administrative and data management infrastructure to the VCID biomarkers consortium. Specific strengths of the proposed MGH coordinating center include 1) the Principal Investigator's demonstrated high-level skill as a scientific pioneer in SVD biomarkers and an effective leader of complex multicenter projects and organizations, 2) an outstanding and experienced team of Administrative and Data Core directors, co-Investigators, and study staff capable of handling all aspects of a complex coordinating center, 3) innovative approaches to multimodal data handling and minimizing inter-scanner variations in MRI data, and 4) detailed organizational plans for efficient high-level decision-making by representative committees, creation of consortium standards for data collection and sharing, consortium-wide communication, and outreach to related external efforts. If selected, the proposed MGH coordinating center will be ideally positioned to lead the consortium to its goals of moving SVD biomarkers to the forefront of VCID clinical trials.

项目概要/摘要脑小血管疾病导致的血管对认知障碍和痴呆（VCID）的影响（SVD）现已被认为是主要的公共卫生威胁。响应 NINDS 的多站点号召致力于识别和验证 SVD 相关 VCID 生物标志物的联盟，我们建议成立马萨诸塞州总医院 (MGH) VCID 生物标志物协调中心。拟议的目标协调中心将提供杰出的科学领导和最先进的行政和 VCID 生物标志物联盟的数据管理基础设施。拟议 MGH 的具体优势协调中心包括 1) 首席研究员作为科学先驱所表现出的高水平技能 SVD 生物标志物和复杂多中心项目和组织的有效领导者，2) 杰出的经验丰富的管理和数据核心主管、联合研究者和研究人员团队处理复杂协调中心的各个方面，3) 多模式数据处理的创新方法最大限度地减少 MRI 数据中扫描仪间的差异，以及 4) 高效高层的详细组织计划由代表委员会做出决策，制定数据收集和联盟标准共享、联盟范围内的沟通以及对相关外部工作的推广。如果选择，建议 MGH 协调中心将处于理想的位置，能够领导联盟实现移动 SVD 的目标生物标志物处于 VCID 临床试验的前沿。